Newron Pharmaceuticals S.p.A.
https://www.newron.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Newron Pharmaceuticals S.p.A.
Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
Deal Watch: Lilly Turns To Oblique For Antibody Discovery
Plus deals involving Lilly/Oblique, Rafael Holdings/Cyclo, ADCendo/Multitude, Ocuvex/Visiox and more.
Freely Available Microbiome Data ‘Atlas’ Could Provide Industry Boost
King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.
Takeda Goes In On Molecular Glue Degraders With Degron Deal
The company will pay $1.2bn in upfront and milestone fees to access Degron’s GlueXplorer platform across multiple therapeutic areas.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Hunter-Fleming
- NeuroNova AB
- Newron Pharmaceuticals SpA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice